ABL1 (E255K)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.E255K
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 2 | Bosutinib | 97.5% | 2.5% | 87.22 |
| 3 | Dasatinib | 97.4% | 2.6% | 87.97 |
| 4 | Axitinib | 97.0% | 3.0% | 93.23 |
| 5 | Nintedanib | 96.5% | 3.5% | 90.23 |
| 6 | Vandetanib | 94.4% | 5.6% | 95.74 |
| 7 | Nilotinib | 94.1% | 5.9% | 96.49 |
| 8 | Repotrectinib | 91.9% | 8.1% | 84.21 |
| 9 | Canertinib | 89.4% | 10.6% | 96.49 |
| 10 | Tivozanib | 89.1% | 10.9% | 92.42 |
| 11 | Brigatinib | 89.0% | 11.0% | 82.96 |
| 12 | Erdafitinib | 88.3% | 11.7% | 95.71 |
| 13 | Pacritinib | 88.1% | 11.9% | 88.64 |
| 14 | Crizotinib | 87.3% | 12.7% | 91.39 |
| 15 | Fedratinib | 83.6% | 16.4% | 96.21 |
| 16 | Dacomitinib | 79.3% | 20.7% | 97.99 |
| 17 | Erlotinib | 74.0% | 25.9% | 99.75 |
| 18 | Sunitinib | 64.9% | 35.1% | 91.73 |
| 19 | Pazopanib | 63.0% | 37.0% | 97.49 |
| 20 | Lenvatinib | 61.0% | 39.0% | 97.74 |
| 21 | Afatinib | 57.6% | 42.4% | 98.50 |
| 22 | Cabozantinib | 53.5% | 46.5% | 92.73 |
| 23 | Imatinib | 53.0% | 47.0% | 99.00 |
| 24 | Ripretinib | 52.4% | 47.6% | 92.95 |
| 25 | Dabrafenib | 51.1% | 48.9% | 94.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 100.0% | 100.0% | +0.0% |
| Bosutinib | 97.5% | 99.7% | -2.2% |
| Dasatinib | 97.4% | 98.6% | -1.3% |
| Axitinib | 97.0% | 99.4% | -2.4% |
| Nintedanib | 96.5% | 99.9% | -3.3% |
| Vandetanib | 94.4% | 95.7% | -1.3% |
| Nilotinib | 94.1% | 98.0% | -3.9% |
| Repotrectinib | 91.9% | 93.6% | -1.7% |
| Canertinib | 89.4% | 91.6% | -2.1% |
| Tivozanib | 89.1% | 95.8% | -6.7% |
| Brigatinib | 89.0% | 82.8% | +6.2% |
| Erdafitinib | 88.3% | 90.9% | -2.7% |
| Pacritinib | 88.1% | 92.0% | -4.0% |
| Crizotinib | 87.3% | 97.0% | -9.7% |
| Fedratinib | 83.6% | 82.7% | +0.9% |
| Dacomitinib | 79.3% | 80.8% | -1.5% |
| Erlotinib | 74.0% | — | — |
| Sunitinib | 64.9% | — | — |
| Pazopanib | 63.0% | 77.5% | -14.5% |
| Lenvatinib | 61.0% | 76.3% | -15.3% |
| Afatinib | 57.6% | — | — |
| Cabozantinib | 53.5% | — | — |
| Imatinib | 53.0% | 86.2% | -33.2% |
| Ripretinib | 52.4% | 82.9% | -30.5% |
| Dabrafenib | 51.1% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| carcinoma_upper_aerodigestive_tract | Stomach/Digestive Tract | ref |
| carcinoma_penis | Genitourinary system | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 67.3ms